Evidence map›Paper›PMID 38459156›Full record

Trial reportAnnals of hematology2024

Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group.

Gabriel Scheubeck, Martin Hoffmann, Vindi Jurinovic, Luca Fischer, Michael Unterhalt, Christian Schmidt, Hans-Peter Böck, Ulrich Dührsen, Joachim Kaesberger, Stephan Kremers and 6 more

Open access · hybridAbstract readMulticenter StudyClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 1 country.

Gabriel ScheubeckDepartment of Internal Medicine III, LMU University Hospital, LMU Munich, Munich, Germany. Gabriel.scheubeck@med.uni-muenchen.de.ORCID http://orcid.org/0009-0004-2546-6154
Martin Hoffmann *Medical Clinic A, Clinical Centre Ludwigshafen, Ludwigshafen, Germany.
Vindi JurinovicInstitute for Medical Information Processing, Biometry, and Epidemiology, LMU Munich, Munich, Germany.
Luca FischerDepartment of Internal Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.
Michael UnterhaltDepartment of Internal Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.
Christian SchmidtDepartment of Internal Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.
Hans-Peter BöckHematology-Oncology practice, Offenbach, Germany.
Ulrich DührsenClinic of Hematology, University Hospital, University of Duisburg-Essen, Essen, Germany.
Joachim KaesbergerInternal Medicine, Diakonieklinikum, Stuttgart, Germany.
Stephan KremersHematology-Oncology, Caritas Hospital Lebach, Lebach, Germany.
Hans-Walter LindemannHematology-Oncology, Catholic Clinic, Hagen, Germany.
Luisa MantovaniHematology-Oncology, St. Georg Clinic, Leipzig, Germany.
Wolfgang HiddemannDepartment of Internal Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.
Eva Hoster *Department of Internal Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.
Martin Dreyling *Department of Internal Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.
German Lymphoma Alliance (GLA)
LMU Klinikum · DEDiakonie-Klinikum Stuttgart · DEKlinikum Ludwigshafen · DEKlinikum St. Georg · DEUniversity of Art and Design Offenbach · DEUniversity of Duisburg-Essen · DEZimmer Biomet (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rituximab, gemcitabine and oxaliplatin (R-GemOx) has demonstrated to be effective and safe in lymphoma patients. We aimed to determine the maximum tolerated dose (MTD) of oxaliplatin in combination with rituximab and gemcitabine and to explore the efficacy and safety of R-GemOx in relapsed or refractory (r/r) indolent and mantle cell lymphoma (MCL). In this single-arm, phase I/II trial, we enrolled 55 patients with r/r indolent lymphoma and MCL not suitable for autologous stem-cell transplantation. Patients received 4 cycles of R-GemOx. In the dose escalation group, 70 mg/m

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsDeoxycytidineGemcitabineLymphoma, Mantle-CellOxaliplatinRituximabAdultAgedAged, 80 and overFemaleGermanyHumansMaleMaximum Tolerated DoseMiddle AgedDeoxycytidineGemcitabineOxaliplatinRituximabFollicular lymphomaMantle cell lymphomaPhase I/II trial, maximum tolerated doseRelapsed or refractory B-cell lymphomaR-GemOx

Identifiers

PMID38459156
PMCPMC11224115
OpenAlexW4392764306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.